Lin, X., Z. Xu, L. Carey, J. Romero, A. Makriyannis, C.J. Hillard, E. Ruggiero, M. Dockum, G. Houk, K. Mackie, P.J. Albrecht, F.L. Rice, and A.G. Hohmann, A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain, 2022. 163(5): p. 834-851.
Ao, Z., H. Cai, Z. Wu, J. Krzesniak, C. Tian, Y.Y. Lai, K. Mackie, and F. Guo, Human Spinal Organoid-on-a-Chip to Model Nociceptive Circuitry for Pain Therapeutics Discovery. Anal Chem, 2022. 94(2): p. 1365-1372.
Lee, M.T., K. Mackie, and L.C. Chiou, Alternative pain management via endocannabinoids in the time of the opioid epidemic: Peripheral neuromodulation and pharmacological interventions. Br J Pharmacol, 2021.
Straiker, A., S. Wilson, W. Corey, M. Dvorakova, T. Bosquez, J. Tracey, C. Wilkowski, K. Ho, J. Wager-Miller, and K. Mackie, An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. Molecules, 2021. 26(17).
Lu, H.C. and K. Mackie, Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging, 2021. 6(6): p. 607-615.
Chen, H.T. and K. Mackie, Adolescent Delta(9)-Tetrahydrocannabinol Exposure Selectively Impairs Working Memory but Not Several Other mPFC-Mediated Behaviors. Front Psychiatry, 2020. 11: p. 576214.
Laszlo, Z.I., Z. Lele, M. Zoldi, V. Miczan, F. Mogor, G.M. Simon, K. Mackie, I. Kacskovics, B.F. Cravatt, and I. Katona, ABHD4-dependent developmental anoikis safeguards the embryonic brain. Nat Commun, 2020. 11(1): p. 4363.
Ao, Z., H. Cai, D.J. Havert, Z. Wu, Z. Gong, J.M. Beggs, K. Mackie, and F. Guo, One-Stop Microfluidic Assembly of Human Brain Organoids To Model Prenatal Cannabis Exposure. Anal Chem, 2020. 92(6): p. 4630-4638.
Straiker, A., M. Dvorakova, A. Zimmowitch, and K. Mackie, Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Mol Pharmacol, 2018. 94(1): p. 743-748.
Lin, X., A.S. Dhopeshwarkar, M. Huibregtse, K. Mackie, and A.G. Hohmann, Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence. Mol Pharmacol, 2018. 93(2): p. 49-62.